Ramasastry Saira 4

What Happened

• Saira Ramasastry, a director of Mirum Pharmaceuticals (MIRM), had 3,977 restricted stock units (RSUs) vest and convert to common shares on May 29, 2026, and those 3,977 shares were sold in the open market on June 1, 2026 at $100.00 per share for total gross proceeds of $397,700. The sale was reported on the Form 4 filed June 2, 2026.
• The Form 4 also records a related conversion/exercise entry for 3,977 derivative units on May 29 (reported with $0 proceeds), which is tied to the RSU vesting and conversion process.

Key Details

• Transaction dates and prices:
  • May 29, 2026: RSUs vested/converted to 3,977 shares (derivative exercise/conversion).
  • June 1, 2026: Open-market sale of 3,977 shares at $100.00 each = $397,700 gross proceeds.
• Footnotes:
  • F1/F3: The reported units were RSUs that vest on May 29, 2026 and convert to one share each (or cash equivalent at the issuer's discretion).
  • F2: The June 1 sale occurred pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on Sept 18, 2025.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Filing timeliness: No late filing indication shown in the provided data.

Context

• This sequence (RSU vest/conversion followed by an immediate open‑market sale) is common when insiders sell shares that have just vested; the sale here was executed under a pre-established 10b5‑1 plan, which automates and documents planned trades.
• Sales are not a direct indicator of company outlook by themselves; they often reflect routine liquidity or tax/compensation management rather than an updated view on the company.